CHARACTERISTICS OF THE HORMONAL STATUS IN PATIENTS WITH CHD AND TYPE 2 DIABETES DUE TO THE METABOLIC SYNDROME USING TELMISARTAN AS PART OF COMPLEX THERAPY
Abstract
CHARACTERISTICS OF THE HORMONAL STATUS IN PATIENTS WITH CHD AND TYPE 2 DIABETES DUE TO THE METABOLIC SYNDROME USING TELMISARTAN AS PART OF COMPLEX THERAPY
References
Chen T, Xing J, Liu Y. Effects of telmisartan on vascular endothelial function, inflammation and insulin resistance in patients with coronary heart disease and diabetes mellitus. Exp. Ther. Med. 2018. Vol. 15(1). P. 909–913.
Telmisartan attenuates obesity-induced insulin resistance via suppression of AMPK mediated ER stress / Y. Huang, Y. Li, Q. Liu et al. Biochem. Biophys. Res. Commun. 2020. Vol. 523(3). P. 787–794. doi: 10.1016/j.bbrc.2019.12.111
Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications / P. Gadge, R. Gadge, N. Paralkar et al. Perspectives Clin. Res. 2018. Vol. 9(4). P. 155.
Telmisartan improves insulin resistance: a meta-analysis / Y. Wang, S. Qiao, D. W. Han et al. Am. J. Therapeut. 2018. Vol. 25(6). P. e642-e651. 5. Anti-diabetic effect of telmisartan through its partial PPARγ-agonistic activity / M. A. Ayza, K. A. Zewdie, B. A. Tesfaye et al. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020. Vol. 13. P. 3627.
Farský Š., Strišková A., Borčin M. Hypertension treatment in patients with metabolic syndrome and/or type 2 diabetes mellitus: analysis of the therapy effectivity and the therapeutic inertia in outpatient study. Cardiology research and practice. 2018.
